treatment options

Analysis of the Use of Duloxetine in the High-dose Range (90 to 120 mg) in the Psychiatric Clinic for the Treatment of Patients With Major Depressive Disorder

Analysis of the Use of Duloxetine in the High-dose Range (90 to 120 mg) in the Psychiatric Clinic for the Treatment of Patients With Major Depressive Disorder

Duloxetine Efficacy in High Doses Duloxetine, a selective serotonin and norepinephrine reuptake inhibitor, has been widely studied for its effectiveness […]

Analysis of the Use of Duloxetine in the High-dose Range (90 to 120 mg) in the Psychiatric Clinic for the Treatment of Patients With Major Depressive Disorder Read Post »

Mapping the evidence-practice gap in pediatric post-traumatic seizures and post-traumatic epilepsy: A national practice-pattern survey of pediatric neurologists

Evidence-Practice Gap The evidence-practice gap refers to the discrepancy between what research suggests as best practices in healthcare and what

Mapping the evidence-practice gap in pediatric post-traumatic seizures and post-traumatic epilepsy: A national practice-pattern survey of pediatric neurologists Read Post »

Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

Study Overview The phase 3 trial known as ENERGIZE-T investigated the efficacy and safety of mitapivat in adults diagnosed with

Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial Read Post »

Scroll to Top